|
Match
|
Document |
Document Title |
|
|
EP1961426A1 |
Combined meningitis vaccines
Addition of a Hib conjugate to meningococcal conjugates enhances the overall activity against meningococcus serogroup W 135.
|
|
|
7410975 |
Small molecule toll-like receptor (TLR) antagonists
The invention provides methods and compositions useful for modulating signaling through Toll-like receptors. The methods involve contacting a TLR-expressing cell with a small molecule having a core...
|
|
|
7402572 |
Immunostimulatory nucleic acid molecules
Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a...
|
|
|
7381807 |
Immunostimulatory oligonucleotides and uses thereof
Oligonucleotides containing the non-palindromic sequence motif:
X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 ,
|
|
|
7375091 |
HER-2/neu fusion proteins
The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and...
|
|
|
7354909 |
Method for rapid generation of mature dendritic cells
Novel methods for rapidly generating dendritic cells are disclosed herein. The methods include contacting a dendritic cell precursor with a D ODN to generate a mature dendritic cell. In one...
|
|
|
7271156 |
Immunostimulatory nucleic acids
The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T...
|
|
|
7255868 |
Chimeric immunomodulatory compounds and methods of using the same—I
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
|
|
|
7229623 |
Her-2/neu fusion proteins
The present invention is generally directed to Her-2/neu fusion proteins, nucleic acid molecules encoding Her-2/neu fusion proteins, viral vectors expressing Her-2/neu fusion proteins, and...
|
|
|
7226998 |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the...
|
|
|
7223741 |
Immunostimulatory nucleic acid molecules
Nucleic acid sequences containing unmethylated CpG dinucleotides that modulate an immune response including stimulating a Th1 pattern of immune activation, cytokine production, NK lytic activity,...
|
|
|
7211253 |
Erythropoietin forms with improved properties
The invention relates to novel modified erythropoietin (EPO) forms such as fusion proteins comprising a Fc portion of an Ig molecule and a target molecule having the biological activity of EPO. By...
|
|
|
7198920 |
HER-2/neu fusion proteins
The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and...
|
|
|
7186804 |
IL-2 fusion proteins with modulated selectivity
The invention provides cytokine fusion proteins with an increased therapeutic index, and methods to increase the therapeutic index of such fusion proteins. The fusion proteins of the invention are...
|
|
|
7169904 |
Immunocytokine sequences and uses thereof
The invention provides a family of antibodies that specifically bind the human cell surface glycosphingolipid GD2. The antibodies comprise modified variable regions, more specially, modified...
|
|
|
7148321 |
Expression technology for proteins containing a hybrid isotype antibody moiety
Disclosed are methods and compositions for efficiently expressing antibody fusion proteins. Antibody fusion proteins of the invention include a hybrid antibody moiety containing sequences from more...
|
|
|
7141651 |
Multiple cytokine protein complexes
The invention relates to protein complexes and fusion proteins including at least two different cytokine molecules. The protein complexes and fusion proteins may further include a targeting moiety...
|
|
|
7108844 |
Use of stabilized oligonucleotides for preparing a medicament with antitumor activity
The invention concerns the use of stabilized oligonucleotides comprising at least an octamer motif of the type: 5′-purine-purine-CG-pyrimidine-pyrimidine-X 1 X 2 -3′ wherein the pair X 1 -X 2 -...
|
|
|
7091321 |
Enhancing the circulating half-life of antibody-based fusion proteins
Disclosed are compositions and methods for enhancing the circulating half-life of antibody-based fusion proteins. Disclosed methods and compositions rely on altering the amino acid sequence of the...
|
|
|
7067110 |
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen...
|
|
|
7038029 |
Immunostimulatory oligonucleotides and uses thereof
Oligonucleotides containing the non-palindromic sequence motif:
X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 ,
|
|
|
7030097 |
Controlled nucleic acid delivery systems
One aspect of the present invention relates to a nucleic acid delivery system including a polymeric structure formed of a biocompatible polymer and a mixture comprising one or more nucleic acid...
|
|
|
7001890 |
Pharmaceutical compositions comprising a polynucleotide and optionally an antigen especially for vaccination
The present invention relates to pharmaceutical compositions comprising at least one fragment of a polynucleotide, preferably at least one antigen, and optionally a pharmaceutically acceptable...
|
|
|
6992174 |
Reducing the immunogenicity of fusion proteins
Disclosed are compositions and methods for producing fusion proteins with reduced immunogenicity. Fusion proteins of the invention include a junction region having an amino acid change that reduces...
|
|
|
6977245 |
Oligodeoxynucleotide and its use to induce an immune response
D type CpG oligodeoxynucleotides are provided herein that include a sequence represented by the following formula:
5′X 1 X 2 X 3 Pu 1 ...
|
|
|
6969517 |
Recombinant tumor specific antibody and use thereof
The invention provides a family of antibodies that specifically bind the human epithelial cell adhesion molecule. The antibodies comprise modified variable regions, more specially, modified...
|
|
|
6951845 |
Method for treating allergic lung disease
The invention is directed to a method for treating both the early and late phases of allergic asthma by introducing naked polynucleotides which operatively encode for the asthma-initiating antigen...
|
|
|
6838260 |
Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulation
Disclosed are methods for producing fusion proteins with the heterodimeric cytokine, interleukin-12. In order to insure that the proper ratio of fused and non-fused subunits are obtained in the...
|
|
|
6737398 |
Modulation of &ggr &dgr T cells to regulate airway hyperresponsiveness
Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of γδ T cells in a patient. Also disclosed are methods for identifying compounds hyperresponsiveness by...
|
|
|
6727230 |
Immune stimulation by phosphorothioate oligonucleotide analogs
Methods of stimulating a local immune response in selected cells or tissues employing immunopotentiating oligonucleotide analogs having at least one phosphorothioate internucleotide bond are...
|